TG Therapeutics, Inc. TGTX
57.43
(0.09)
(0.16%)
as of 25 Sep
- Market cap
- $8.8B
- P/E
- 18.9×
Follow TGTX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
111.96% | 102.75% | 112.60% | 100.28% | |
| 55.55% | 54.50% | 42.27% | 37.70% | ||
ROIC |
8.91% | 10.25% | 11.48% | 10.69% | |
Return on Tangible Assets |
101.02% | 93.75% | 51.33% | 50.33% | |
Average Days of Receivables |
182.11 | 181.01 | 204.32 | 183.32 | |
Free Cash Flow per Share |
(0.48) | (0.17) | (0.10) | 0.12 | |
Free Cash Flow |
(70.24) | (24.99) | (14.19) | 17.39 | |
Capital Expenditures |
(0.17) | (0.21) | (0.24) | (0.49) | |
Piotroski F-Score |
4.00 | 4.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(7.12%) | (2.39%) | (0.76%) | 0.94% | |
Accounts Receivable Turnover |
2.79 | 2.83 | 2.41 | 2.53 | |
Accounts Payable Turnover |
0.73 | 1.21 | 0.84 | 0.81 | |
Inventory Turnover |
0.67 | 0.85 | 0.83 | 0.93 | |
Average Days of Payables |
525.86 | 389.62 | 457.76 | 553.42 | |
Days of Inventory on Hand |
687.91 | 455.14 | 396.82 | 383.22 | |
Tax Rate |
4.10 | 3.16 | 2.78 | 3.35 | |
Research and Development Expense of Revenue |
26.24% | 26.00% | 22.95% | 28.05% | |
Selling, General and Administrative Expense of Revenue |
39.78% | 37.65% | 38.76% | 37.27% | |
Share Based Compensation of Revenue |
11.46% | 10.49% | 9.94% | 10.15% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.16) | (0.06) | (0.03) | 0.04 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.05 | 0.09 | 0.18 | 1.42 | |
Revenue per Share |
3.66 | 4.27 | 4.85 | 5.64 | |
Operating CF per Share |
(0.48) | (0.17) | (0.10) | 0.13 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
84.13% | 72.56% | 65.95% | 55.22% |
Columns are period end dates